Both daratumumab and isatuximab have been shown to effectively induce myeloma cell death via Fc-dependent mechanisms of action and the depletion of CD38+ immunosuppressive cells [183,184,185,186,187,188]. Here, CD38 is linked to plasma cell myeloma.